Brittany L Murphy1, Min Yi1, Banu K Arun2, Angelica M Gutierrez Barrera2, Isabelle Bedrosian3. 1. Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. ibedrosian@mdanderson.org.
Abstract
BACKGROUND: An increasing number of breast cancer patients are undergoing expanded genetic testing and are being identified as germline mutation carriers. We sought to determine rates of contralateral risk-reducing mastectomy (CRRM) in patients with various germline mutations. PATIENTS AND METHODS: All women ≥ 18 years of age with unilateral breast cancer who underwent multigene panel testing between January 1, 2014 and August 1, 2019 at our academic institution were identified. Demographic, tumor, and treatment variables were identified from the medical record. Multivariable analyses were performed to compare factors associated with performance of CRRM. RESULTS: We identified 1613 patients, of whom 28.1% had a pathogenic variant and 40.1% had variants of uncertain significance (VUS). Overall, 420 patients (26.0%) underwent a CRRM. On multivariable analysis, factors associated with CRRM included age < 50 years (OR 3.8, 95% CI 3.0, 5.0), race (OR 0.5, 95% CI 0.3, 0.7 and OR 0.4, 95% CI 0.2, 0.7 for Black and Asian women, respectively, versus White women), and the presence of any germline mutation or VUS (OR 13.2, 95% CI 8.7, 20.2 for BRCA1/2; OR 3.9, 95% CI 2.7, 5.8 for non-BRCA germline mutation; and OR 1.8, 95% CI 1.3, 2.6 for VUS). CONCLUSIONS: In breast cancer patients who undergo multigene panel testing, a sizeable number of women with pathogenic non-BRCA germline findings are opting for CRRM. Given that the risk of contralateral breast cancer in women with most pathogenic mutations other than BRCA1/2 remains poorly characterized, these data have implications for risk counseling and for ascertaining the true risks of contralateral breast cancer in this population.
BACKGROUND: An increasing number of breast cancerpatients are undergoing expanded genetic testing and are being identified as germline mutation carriers. We sought to determine rates of contralateral risk-reducing mastectomy (CRRM) in patients with various germline mutations. PATIENTS AND METHODS: All women ≥ 18 years of age with unilateral breast cancer who underwent multigene panel testing between January 1, 2014 and August 1, 2019 at our academic institution were identified. Demographic, tumor, and treatment variables were identified from the medical record. Multivariable analyses were performed to compare factors associated with performance of CRRM. RESULTS: We identified 1613 patients, of whom 28.1% had a pathogenic variant and 40.1% had variants of uncertain significance (VUS). Overall, 420 patients (26.0%) underwent a CRRM. On multivariable analysis, factors associated with CRRM included age < 50 years (OR 3.8, 95% CI 3.0, 5.0), race (OR 0.5, 95% CI 0.3, 0.7 and OR 0.4, 95% CI 0.2, 0.7 for Black and Asian women, respectively, versus White women), and the presence of any germline mutation or VUS (OR 13.2, 95% CI 8.7, 20.2 for BRCA1/2; OR 3.9, 95% CI 2.7, 5.8 for non-BRCA germline mutation; and OR 1.8, 95% CI 1.3, 2.6 for VUS). CONCLUSIONS: In breast cancerpatients who undergo multigene panel testing, a sizeable number of women with pathogenic non-BRCA germline findings are opting for CRRM. Given that the risk of contralateral breast cancer in women with most pathogenic mutations other than BRCA1/2 remains poorly characterized, these data have implications for risk counseling and for ascertaining the true risks of contralateral breast cancer in this population.
Authors: Saundra S Buys; John F Sandbach; Amanda Gammon; Gayle Patel; John Kidd; Krystal L Brown; Lavania Sharma; Jennifer Saam; Johnathan Lancaster; Mary B Daly Journal: Cancer Date: 2017-01-13 Impact factor: 6.860
Authors: Patricia A Parker; Susan K Peterson; Isabelle Bedrosian; Melissa A Crosby; Yu Shen; Dalliah M Black; Gildy Babiera; Henry M Kuerer; Jun Ying; Wenli Dong; Scott B Cantor; Abenaa M Brewster Journal: Ann Surg Date: 2016-01 Impact factor: 12.969
Authors: Holly J Pederson; Dharmesh Gopalakrishnan; Ryan Noss; Courtney Yanda; Charis Eng; Stephen R Grobmyer Journal: J Am Coll Surg Date: 2018-01-31 Impact factor: 6.113
Authors: Fergus J Couch; Hermela Shimelis; Chunling Hu; Steven N Hart; Eric C Polley; Jie Na; Emily Hallberg; Raymond Moore; Abigail Thomas; Jenna Lilyquist; Bingjian Feng; Rachel McFarland; Tina Pesaran; Robert Huether; Holly LaDuca; Elizabeth C Chao; David E Goldgar; Jill S Dolinsky Journal: JAMA Oncol Date: 2017-09-01 Impact factor: 31.777
Authors: Nisreen Elsayegh; Rachel D Webster; Angelica M Gutierrez Barrera; Heather Lin; Henry M Kuerer; Jennifer K Litton; Isabelle Bedrosian; Banu K Arun Journal: Cancer Med Date: 2018-05-07 Impact factor: 4.452
Authors: Maren Weischer; Børge G Nordestgaard; Paul Pharoah; Manjeet K Bolla; Heli Nevanlinna; Laura J Van't Veer; Montserrat Garcia-Closas; John L Hopper; Per Hall; Irene L Andrulis; Peter Devilee; Peter A Fasching; Hoda Anton-Culver; Diether Lambrechts; Maartje Hooning; Angela Cox; Graham G Giles; Barbara Burwinkel; Annika Lindblom; Fergus J Couch; Arto Mannermaa; Grethe Grenaker Alnæs; Esther M John; Thilo Dörk; Henrik Flyger; Alison M Dunning; Qin Wang; Taru A Muranen; Richard van Hien; Jonine Figueroa; Melissa C Southey; Kamila Czene; Julia A Knight; Rob A E M Tollenaar; Matthias W Beckmann; Argyrios Ziogas; Marie-Rose Christiaens; Johanna Margriet Collée; Malcolm W R Reed; Gianluca Severi; Frederik Marme; Sara Margolin; Janet E Olson; Veli-Matti Kosma; Vessela N Kristensen; Alexander Miron; Natalia Bogdanova; Mitul Shah; Carl Blomqvist; Annegien Broeks; Mark Sherman; Kelly-Anne Phillips; Jingmei Li; Jianjun Liu; Gord Glendon; Caroline Seynaeve; Arif B Ekici; Karin Leunen; Mieke Kriege; Simon S Cross; Laura Baglietto; Christof Sohn; Xianshu Wang; Vesa Kataja; Anne-Lise Børresen-Dale; Andreas Meyer; Douglas F Easton; Marjanka K Schmidt; Stig E Bojesen Journal: J Clin Oncol Date: 2012-10-29 Impact factor: 44.544
Authors: M Kriege; A Hollestelle; A Jager; P E A Huijts; E M Berns; A M Sieuwerts; M E Meijer-van Gelder; J M Collée; P Devilee; M J Hooning; J W M Martens; C Seynaeve Journal: Br J Cancer Date: 2014-06-10 Impact factor: 7.640
Authors: Jacob G Comeaux; Julie O Culver; John E Lee; Danielle Dondanville; Heather L McArthur; Emily Quinn; Nicholas Gorman; Charité Ricker; Ming Li; Caryn Lerman Journal: Mol Genet Genomic Med Date: 2022-08-25 Impact factor: 2.473